APA (7th ed.) Citation

M, J., J, v. P., S, K., JR, F., W, E., TC, G., . . . U, J. (2016). Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Annals of oncology : official journal of the European Society for Medical Oncology, 27(10), 1895. https://doi.org/10.1093/annonc/mdw290

Chicago Style (17th ed.) Citation

M, Joerger, et al. "Open-label, Randomized Study of Individualized, Pharmacokinetically (PK)-guided Dosing of Paclitaxel Combined with Carboplatin or Cisplatin in Patients with Advanced Non-small-cell Lung Cancer (NSCLC)." Annals of Oncology : Official Journal of the European Society for Medical Oncology 27, no. 10 (2016): 1895. https://doi.org/10.1093/annonc/mdw290.

MLA (9th ed.) Citation

M, Joerger, et al. "Open-label, Randomized Study of Individualized, Pharmacokinetically (PK)-guided Dosing of Paclitaxel Combined with Carboplatin or Cisplatin in Patients with Advanced Non-small-cell Lung Cancer (NSCLC)." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 10, 2016, p. 1895, https://doi.org/10.1093/annonc/mdw290.